These results indicated that downregulation of LDOC1 in lung cancer was associated with a poor prognosis, especially for shorter OS, suggesting that LDOC1 is a potential biomarker for the clinical outcome of patients with lung cancer. This evidence concerns the gene LDOC1 and lung cancer.